Related Experiment Video
Updated: Jul 11, 2026
08:33
A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
Published on: January 5, 2024
[Fibromyalgia syndrome: new developments in pharmacotherapy].
1Schwerpunkt Rheumatologie, Sophienblatt 1, 24103, Kiel, Deutschland. p.harten@web.de
Zeitschrift Fur Rheumatologie
|October 10, 2007
Summary
Newer medications show promise for fibromyalgia syndrome (FMS), a condition affecting millions. This review examines evidence-based pharmacological treatments for FMS, offering hope for improved patient outcomes.
Area of Science:
- Pharmacology
- Clinical Medicine
- Rheumatology
Context:
- Fibromyalgia syndrome (FMS) impacts 2-10% of adults in industrialized nations.
- Current FMS treatments are often unsatisfactory, leading to significant morbidity and disability.
- Recent years have seen a surge in clinical trials for FMS management.
Purpose:
- To review randomized, controlled studies of novel pharmacological treatments for fibromyalgia syndrome.
- To provide an evidence-based overview of emerging medical therapies for FMS.
Summary:
- Focuses on newer drug classes including selective serotonin/norepinephrine reuptake inhibitors (e.g., duloxetine, milnacipran).
- Evaluates voltage-gated calcium channel inhibitors (e.g., pregabalin, gabapentin) and dopamine agonists (e.g., pramipexole).
- Includes other agents like sodium oxybate, modafinil, dronabinol, tropisetron, tramadol, dextromethorphan, and olanzapine.
Impact:
- Highlights evidence-based, newer pharmacologic options for FMS treatment.
- Aims to inform clinicians about effective, emerging medical interventions for fibromyalgia.
- Contributes to improving treatment strategies for a widespread, disabling condition.
Related Concept Videos
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:24Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...